bullish
Acadia Pharma: Hedge Fund Favorite and Upcoming Catalyst.
501 Views09 Dec 2016 05:51
We took another look at P2 trial design for Acadia Pharmaceuticals Inc (ACAD US) Alzheimer's disease Psychosis ADP trial (results expected later...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset15 Mar 2018
- Acadia Pharma: Hedge Fund Favorite and Upcoming Catalyst.09 Dec 2016
- New Long Position: Novel Drug for Wet-AMD, a Common Cause of Blindness, and Upcoming Catalyst.06 Dec 2016
- New Long Position: Gene Therapy for Parkinson's Disease and Upcoming Catalysts05 Dec 2016
x